One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, single-arm, open-label study investigating the safety,
compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6
in renal transplant candidates.